KRAS and metastatic colorectal cancer: The above results suggest that this therapeutic regimen is a promising treatment modality for the management of pretreated, <i>MSS</i>-type and <i>KRAS</i>-mutated metastatic colorectal cancer although its application to the general public still needs to be validated in clinical trials.